Dr Siegall Pushes Further Towards The Treatment Of Cancer
With more than twenty years of experience in cancer research and treatment, Dr Clay Siegall passion and commitment to cure cancer continues to fuel even more. He is the current co-founder chief executive officer of Seattle Genetics. Seattle Genetics is a biotechnology company whose main purpose if in finding therapies that aid in cancer treatment. As the chief executive officer Mr Siegall has spearheaded the company into production of ADC therapies that have received the approval of FDA. He has also led the company in the establishment and launch of ADCETRIS, an antibody drug conjugate that is being sold and used in more than sixty countries around the world.
His passion for medicine and especially oncology began after graduating from the University of Maryland with a bachelor’s degree in Zoology and later joined the George Washington University with a Ph.D IN Genetics. From there he worked at The National Cancer Institute as a staff and biotechnology fellow. He worked as a senior research investigator at Bristol-Myers Squibb Pharmaceutical Research Institute.
At Seattle Genetics, he works alongside his team to achieve their purpose in the treatment of cancer. He also led the company into several multi-million dollar deals for their ADC technology. He has also helped the company in achieving more than 1.2 billion of funds through inviting the public and private sectors to finance. He also pushes his team towards generating and coming up with more therapies that may help their patients across the world.
Through his career, he has always shown his determination in getting the cure and treatment of cancer. His empathy towards cancer drives him each day to work towards the cure. His efforts have been noticed through the publications he has written that help people understand cancer and how to make their loves more comfortable. He was also named the entrepreneur of the year by Ernst & Young.
Recently, Forbes wrote an article revealing that the company’s drugs were tested and found that they had created an impact on their patients. The patients who were given the brentuximab vedotin Adcetris were doing better than those who hadn’t. Which makes the drug quite valuable to the patients